METHOD FOR PREDICTING SENSITIVITY TO NEOADJUVANT THERAPY IN PATIENTS WITH BREAST CANCER

摘要

The invention relates to a method for predicting the sensitivity to the neoadjuvant therapy in the patient with breast cancer consisting in assaying ferritin content in blood serum by enzyme-linked immunosorbent assay prior to the first course of neoadjuvant chemotherapy. When ferritin content is less than 200 ng/mL, the high sensitivity of breast cancer to the neoadjuvant chemotherapy is predicted. The ferritin content ≥ 200 ng/mL suggests the resistance to the neoadjuvant chemotherapy.